🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  2. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  3. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington Disease

    phase 2 small molecule completed

    2 trials

  4. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Mild Cognitive Impairment

    phase 2 small molecule completed

    1 trial

  5. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  6. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  7. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  8. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  9. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  10. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  11. SCB01A

    Biotech Pharmaceutical Co.,

    Head and Neck Neoplasms

    phase 2 small molecule terminated

    1 trial

  12. SCD-044 Tablets 0.1mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 0.3mg, SCD-044 Tablets 1.0mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    atopic dermatitis

    phase 2 small molecule active

    1 trial

  13. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  14. SHJ002/Vehicle

    Biotech Pharmaceutical Co.,

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  15. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  16. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  18. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  19. SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion, SIROLIMUS, PREDNISONE, METHYLPREDNISOLONE SODIUM SUCCINATE, PARACETAMOL, Epysqli 300 mg concentrate for solution for infusion, PREDNISONE, DIPHENHYDRAMINE HYDROCHLORIDE, SIROLIMUS, PREDNISONE, RITUXIMAB, RITUXIMAB, ECULIZUMAB, BEKEMV 300 mg concentrate for solution for infusion, AAV9.LAMP2B, DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE, SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Danon Disease

    phase 2 small molecule active

    1 trial

  20. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  21. SNDX-6352

    Syndax Pharmaceuticals

    Coronavirus

    phase 2 small molecule terminated

    1 trial

  22. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  23. SODIUM CHLORIDE, ADALIMUMAB, LAD191, LAD191 placebo

    Almirall, S.A.

    Moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  24. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources